Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

tPA tissue plasminogen activator is produced by using recombinant technology techniques known as recombinant tissue plasminogen activator (rtPA). Specific rtPAs are tenecteplase, alteplase, and reteplase. These enzymes are used in clinical treatment of thrombotic stroke or embolic stroke. tPA is a drug that dissolves blood clots. It is a thrombolytic agent which can be administrated into the veins.

Rising burden of pulmonary embolism in individuals globally, is expected to propel the growth of the market over the forecast period.

For instance, according to Centers for Disease Control and Prevention report published in 2019, approximately 900,000 Americans were affected due to pulmonary embolism and about 10-20 % individuals die after 1 month of diagnosis.

The global tissue plasminogen activator market is estimated to be valued at US$ 2,455.4 million in 2022 and is expected to exhibit a CAGR of 5.2% over the forecast period (2020-2027).

Figure 1. Global Tissue Plasminogen Activator Market Share (%) in Terms of Value, By Region, 2020

Tissue Plasminogen Activator  | Coherent Market Insights

Increasing Incidence of Stroke is expected to drive the market growth over the forecast period

Tissue plasminogen activator (tPA) is an enzyme associated with the disintegration of blood clots. It is a serine protease present in endothelial cells. With the help of serine protease, the conversion of plasminogen to plasmin is catalyzed.  Serine protease is a major enzyme for clot disintegration.

Tissue plasminogen activator is the first and only drug approved by the U.S. FDA in 1996 for the treatment of acute ischemic stroke. The increasing incidence of stroke is expected to drive the market growth during the forecast period.

For instance, according to the World Health Organization (WHO), in 2015, stroke is the second leading global cause of death after heart disease and it accounted for 11.8% of total deaths worldwide.

Furthermore, according to the Centers for Disease Control and Prevention, in 2018, 1 in every 6 deaths from cardiovascular disease was due to stroke in the U.S.

Figure 2. Global Tissue Plasminogen Activator Market Share (%), by Drug Type, 20220

Tissue Plasminogen Activator  | Coherent Market Insights

The increasing prevalence of stroke in growing geriatric population is another major factor driving the market size. As per the Public Health England (PHE), around 38% of people suffering from strokes were aged between 40 to 69 years in 2018.

Moreover, tissue plasminogen activator market revenue is witnessing further increase due to awareness about stroke and its symptoms. In 2015, the Centers for Disease Control and Prevention (CDC) stated that around 38% of people were able to recognize the major symptoms of stroke and were treated at the right time.

request-sample

Tissue Plasminogen Activator Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2022: US$ 2,455.4 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2020 to 2027
Forecast Period 2021 to 2028 CAGR: 5.2% 2027 Value Projection: US$  3,491.5 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Type: Alteplase, Reteplase, Tenecteplase
  • By Application: Ischemic Stroke, Myocardial Infarction, Pulmonary Embolism, Thrombolysis, Others
Companies covered:

F. Hoffmann-La Roche AG, Boehringer Ingelheim GmbH, CHIESI Farmaceutici S.p.A., Gennova Biopharmaceuticals Ltd, Abbott Laboratories, and Reliance Life Sciences

Growth Drivers:
  • Increasing number of pipeline product
  • Increasing prevalence of stroke
Restraints & Challenges:
  • Side effect of tissue plasminogen activator drugs

Global Tissue Plasminogen Activator Market– Impact of Coronavirus (Covid-19) Pandemic

The tissue plasminogen activators such as alteplase, reteplase, and tenecteplase have wide application for treatment of disease conditions such as ischemic stroke, myocardial Infarction, pulmonary embolism, and deep vein thrombosis. Moreover, many patients suffering from cardiovascular diseases such as ischemia heart diseases, hypertension, and others are at a higher risk of contracting COVID-19. Thus, for the treatment of these symptoms along with COVID-19, doctors prescribe drugs such as hydroxychloroquine, azithromycin, and altepase, and this has had a positive impact on the global tissue plasminogen activator market during COVID-19.    

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it as a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus disease (COVID-19) has resulted in more than 136 million infected individuals worldwide as of April 12, 2021.

COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to the transportation of drugs and devices from one place to another.

Global Tissue Plasminogen Activator Market Restraint

The side effects such as nausea, vomiting, dizziness, and fever, of the tissue plasminogen activator drugs is one of the factors hindering tissue plasminogen activator market growth. Major side effects include hypertension, intracranial hemorrhage, systemic hemorrhage, angioedema, and others. tPA causes complications of left ventricle as well.

According to the National Center for Biotechnology Information, around 2% to 5% of patients with acute ischemic stroke received rtPA in the U.S. In 2015, Centers for Disease Control and Prevention (CDC) reported around 140,000 deaths due to unavailability and adverse effects of tPA in the U.S.

Moreover, tissue plasminogen activator market growth can be hampered by substitute product approvals by the U.S. Food and Drug Administration (FDA). For instance, after the approval of stent retriever by the U.S. FDA in 2012, the global tissue plasminogen activator market growth was affected, since tPA is not effective for major blood clots in comparison to the stent retriever thrombectomy.

Key Players

Major players operating in the global tissue plasminogen activator market include include F. Hoffmann-La Roche AG, Boehringer Ingelheim GmbH, CHIESI Farmaceutici S.p.A., Gennova Biopharmaceuticals Ltd, Abbott Laboratories, and Reliance Life Sciences

Tissue plasminogen activator (tPA) is an enzyme associated with the disintegration of blood clots. It is a serine protease present in endothelial cells. With the help of serine protease, the conversion of plasminogen to plasmin is catalyzed. Serine protease is a major enzyme for clot disintegration.

Market Dynamics

The increasing prevalence of ischemic strokes is expected to drive growth of the global tissue plasminogen activator market over the forecast period. For instance, Institute for Health Metrics and Evaluation report published in 2019, ischemia heart stroke accounted for around 63.5 million (95% UI 57·8–69·0) people globally. Ischemic stroke was responsible for 3.29 million (2·97–3·54) deaths in 2019 globally, with 3.45 million (2·96–4·03) incident cases in males and 4.19 million (3·61–4·91) in females.

Key features of the study:

  • This report provides in-depth analysis of the global tissue plasminogen activator market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global tissue plasminogen activator market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include F. Hoffmann-La Roche AG, Boehringer Ingelheim GmbH, CHIESI Farmaceutici S.p.A., Gennova Biopharmaceuticals Ltd, Abbott Laboratories, and Reliance Life Sciences
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global tissue plasminogen activator market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global tissue plasminogen activator market

Detailed Segmentation:

  • Global Tissue Plasminogen Activator Market, By Drug Type:
    • Alteplase
    • Reteplase
    • Tenecteplase
  • Global Tissue Plasminogen Activator Market, By Application:
    • Ischemic Stroke
    • Myocardial Infarction
    • Pulmonary Embolism
    • Thrombolysis
    • Others
  • Global Tissue Plasminogen Activator Market, By Region:
    • North America
      • By Drug Type
        • Alteplase
        • Reteplase
        • Tenecteplase
      • By Application
        • Ischemic Stroke
        • Myocardial Infarction
        • Pulmonary Embolism
        • Thrombolysis
        • Others
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Drug Type
        • Alteplase
        • Reteplase
        • Tenecteplase
      • By Application
        • Ischemic Stroke
        • Myocardial Infarction
        • Pulmonary Embolism
        • Thrombolysis
        • Others
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Type
        • Alteplase
        • Reteplase
        • Tenecteplase
      • By Application
        • Ischemic Stroke
        • Myocardial Infarction
        • Pulmonary Embolism
        • Thrombolysis
        • Others
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Type
        • Alteplase
        • Reteplase
        • Tenecteplase
      • By Application
        • Ischemic Stroke
        • Myocardial Infarction
        • Pulmonary Embolism
        • Thrombolysis
        • Others
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Type
        • Alteplase
        • Reteplase
        • Tenecteplase
      • By Application
        • Ischemic Stroke
        • Myocardial Infarction
        • Pulmonary Embolism
        • Thrombolysis
        • Others
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Type
        • Alteplase
        • Reteplase
        • Tenecteplase
      • By Application
        • Ischemic Stroke
        • Myocardial Infarction
        • Pulmonary Embolism
        • Thrombolysis
        • Others
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • F. Hoffmann-La Roche AG *
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Boehringer Ingelheim GmbH
    • CHIESI Farmaceutici S.p.A.
    • Gennova Biopharmaceuticals Ltd
    • Abbott Laboratories
    • Reliance Life Sciences

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Application
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trend
    • Epidemiology
    • Key Developments
    • Regulatory Scenario
    • PEST Analysis
    • Pipeline Analysis
    • Historical Overview
  4. Global Tissue Plasminogen Activator Market – Impact of Coronavirus (Covid-19) Pandemic
    • COVID-19 Impact on Overall Healthcare Sector
    • COVID-19 Epidemiology
    • COVID-19 Impact on Clinical Trials and Drug Development
  5. Global Tissue Plasminogen Activator Market, By Drug Type, 2020 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Alteplase
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
    • Reteplase
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
    • Tenecteplase
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
  6. Global Tissue Plasminogen Activator Market, By Application, 2020 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Ischemic Stroke
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
    • Myocardial Infarction
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
    • Pulmonary Embolism
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
    • Thrombolysis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
  7. Global Tissue Plasminogen Activator Market, By Region, 2020 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • North America
      • Market Size and Forecast, By Drug Type, 2020 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2020 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2020 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Drug Type, 2020 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2020 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2020 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Drug Type, 2020 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2020 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2020 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Type, 2020 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2020 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2020 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Drug Type, 2020 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2020 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2020 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug Type, 2020 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2020 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2020 – 2027, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  8. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • F. Hoffmann-La Roche AG *
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Boehringer Ingelheim GmbH
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • CHIESI Farmaceutici S.p.A.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Gennova Biopharmaceuticals Ltd
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Abbott Laboratories
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Reliance Life Sciences
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 26 market data tables and 29 figures on "Tissue Plasminogen Activator Market” - Global forecast to 2027

Frequently Asked Questions

The global tissue plasminogen activator market size is estimated to be valued at US$ 2,455.4 million in 2021 and is expected to exhibit a CAGR of 5.2% between 2020 and 2027.
Rising prevalence of stroke and number of pipeline products are expected to drive the market growth over the forecast period
Alteplase segment is expected to hold the major market share, owing to increasing product approvals and launches during the forecast period.
North America holds the largest market share in the market
Major factor hampering growth of the market includes side effect of tissue plasminogen activator drugs.
Major players operating in the market include F. Hoffmann-La Roche AG, Boehringer Ingelheim GmbH, CHIESI Farmaceutici S.p.A., Gennova Biopharmaceuticals Ltd, Abbott Laboratories, and Reliance Life Sciences
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner